Native macrophages genetically modified to express heme oxygenase 1 protect rat liver transplants from ischemia/reperfusion injury

Xiu‐Da Shen, Bibo Ke, Yoichiro Uchida, Haofeng Ji, Feng Gao, Yuan Zhai, Ronald W. Busuttil, Jerzy W. Kupiec‐Weglinski – 27 October 2010 – We investigated whether native macrophages overexpressing heme oxygenase 1 (HO‐1) could protect rat orthotopic liver transplant (OLT) against cold ischemia/reperfusion injury (IRI). Livers from Sprague‐Dawley rats were stored at 4°C in University of Wisconsin solution for 24 hours, and then they were transplanted into syngeneic recipients.

Hepatitis C pharmacogenetics: State of the art in 2010

Nezam H. Afdhal, John G. McHutchison, Stefan Zeuzem, Alessandra Mangia, Jean‐Michel Pawlotsky, Jeffrey S. Murray, Kevin V. Shianna, Yasuhito Tanaka, David L. Thomas, David R. Booth, David B. Goldstein, for the Pharmacogenetics and Hepatitis C Meeting Participants – 26 October 2010 – In 2009, a correlated set of polymorphisms in the region of the interleukin‐28B (IL28B) gene were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon‐alfa and ribavirin.

Quantitation of pretreatment serum interferon‐γ–inducible protein‐10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response

Jama M. Darling, Jeroen Aerssens, Gregory Fanning, John G. McHutchison, David B. Goldstein, Alexander J. Thompson, Kevin V. Shianna, Nezam H. Afdhal, Michael L. Hudson, Charles D. Howell, Willem Talloen, Jacques Bollekens, Mieke De Wit, Annick Scholliers, Michael W. Fried – 26 October 2010 – Polymorphisms of the IL28B gene are highly associated with sustained virological response (SVR) in patients with chronic hepatitis C treated with peginterferon and ribavirin. Quantitation of interferon‐γ–inducible protein‐10 (IP‐10) may also differentiate antiviral response.

Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C Virus 1 year after liver transplantation

Pinelopi Manousou, Amar P. Dhillon, Graziela Isgro, Vincenza Calvaruso, T.V. Luong, Emmanuel Tsochatzis, E. Xirouchakis, G. Kalambokis, Timothy J. Cross, N. Rolando, James O'Beirne, David Patch, D. Thornburn, Andrew K. Burroughs – 21 October 2010 – Clinical outcomes of recurrent hepatitis C virus after liver transplantation are difficult to predict. We evaluated collagen proportionate area (CPA), a quantitative histological index, at 1 year with respect to the first episode of clinical decompensation.

Subscribe to